Articles related to ANTI-PSYCHOTICS
Haloperidol for the Treatment of Delirium in ICU Patients
In this randomized study of 1,000 patients with delirium admitted to the ICU, patients receiving haloperidol showed no significant difference in survival compared with patients who received placebo.
Neurology November 1st 2022
What We Can Learn from New Findings on Antipsychotics Dosages
This review of three recent publications in Schizophrenia Bulletin, Expert Opinion in Pharmacotherapy, and Frontiers in Psychiatry highlights some potential opportunity to change standard practice and improve patient outcomes. Emerging research indicates that once-daily dosing before bed is likely effective, reduces adverse effects, and boosts adherence. Furthermore, when switching agents, immediate discontinuation may be preferable, with no need to taper.
Psychiatry October 20th 2022
Perioperative Gabapentin Use and In-Hospital Adverse Clinical Events Among Older Adults After Major Surgery
Gabapentin has been increasingly used as part of a multimodal analgesia regimen to reduce opioid use in perioperative pain management. In this cohort study of 237,872 adults aged 65 years or older, perioperative gabapentin users had significantly increased risk of delirium, new antipsychotic use, and pneumonia compared with nonusers after major surgery.
Anesthesiology October 3rd 2022
Off-Label Use of Low-Dose Quetiapine for MACE and More
Despite having anti-psychotic, anxiolytic, sedative, and hypnotic properties, quetiapine is linked to an increased risk of cardiovascular death and sudden cardiac death when used in conventional doses. For the first time, the current investigation demonstrated that quetiapine taken off-label and in modest doses raises the risk of major adverse cardiovascular events (MACE), stroke, and cardiovascular death.
Cardiology September 19th 2022
Long-term Outcomes of Early Use of Long-Acting Injectable Antipsychotics in Schizophrenia
The authors concluded that, after reviewing the 13-year-study, “switching to LAIs during the first 3 years of treatment improved antipsychotic adherence, decreased relapses, and reduced long-term mortality.” With few studies available comparing the long-term effectiveness between patients who switched to LAIs and those who remained on oral antipsychotics (OAPs), they hope the evidence presented supports the benefits of early LAI treatment in schizophrenia.
Psychiatry June 13th 2022